Dr. Jian Z. Guan

Weei-chin Lin is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Lin is rated as an Experienced provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Retinoblastoma, Ovarian Cancer, and Breast Cancer. Dr. Lin is currently accepting new patients.

Faye Johnson is an Oncologist in Houston, Texas. Dr. Johnson is rated as a Distinguished provider by MediFind in the treatment of Retinoblastoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Squamous Cell Skin Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.